Sleuth published a report showing that Novartis has built an impressive moat with 600+ RLT clinical trial sites, ~1.5K+ therapy centers, and a redundant US manufacturing network allowing for a 2-week turnaround from diagnosis to delivery.
Public source
Publisher name
Public post
Radiopharma market map ☢️ 75+ companies segmented by radioisotope and highest stage of development. Two thoughts about how this space has evolved: 1. While we've seen mo…
Company
Sleuth
Sleuth helps strategic biopharma teams get to conviction faster, turning complex questions into clear answers - in hours
- Industry
- Software Development
- Location
- San Francisco, US
- Company size
- 11–50 employees
About Sleuth
Sleuth replaces patchworks of database subscriptions, consulting engagements, and internal spreadsheets - whether your team runs the analysis or ours does.
See moreLatest activity
Latest activity from Sleuth
9 signals
Research & Knowledge
Sleuth published a report showing that Novartis is the single player with the infrastructure and know-how to operate a radiopharma franchise at global, franchise scale, including 600+ RLT clinical trial sites globally.
Research & Knowledge
Sleuth published a report showing that Novartis has ~1.5K+ therapy centers specialized in administration and treatment, with about half outside the US.
Research & Knowledge
Sleuth published a report showing that Novartis has gone all-in since 2017, with a commitment of over $12B in disclosed potential consideration across 13+ deals, including takeouts of AAA ($3.9B, brought Lutathera), Endocyte ($2.1B, brought Pluvicto), and Mariana Oncology ($1.75B), with Lutathera and Pluvicto generating $1.8B in sales through H1 2026.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Zymewire
Zymewire published a report looking at the companies behind every oral small molecule in Phase 1 or Phase 2 across North America and Europe, and what they have raised in the past two years.
Research & Knowledge
RxClarity
RxClarity published the first edition of RxClarity Weekly Signals covering oncology developments across clinical data, regulatory decisions, deals, and pipeline moves.
Research & Knowledge
LucidQuest
LucidQuest published the H1 2026 Healthcare and Pharma Trends Report examining developments across 14 major therapy areas and healthcare sectors.
Research & Knowledge
Medidata Solutions
Medidata Solutions published an article titled From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting by the Global Costing Taskforce.
Research & Knowledge
Stealth Mode